Penn Bioinvestor

Antigenics Should Rise on the Promise of Cancer Immunotherapy Treatments

VFC, apparently you don't know much about drug discovery. This kind of pump for AGEN is simply naive. Put this way, yes, some previous biotech stocks you pumped do went up well, but it is NOT because you really understand the science behind, but simply because at that time, market is strong for biotech sector as a whole. Enough is enough, please stop here.